Bonalive is a smart biomaterials company transforming the future of healthcare. With one of the most evidence-based technologies in the industry, we are creating a smarter future for healthcare. Bonalive is an ISO 13485:2016 certified, Class III medical device company.
Dr. Ollila founded Bonalive Biomaterials Ltd in 2009, through an MBO of the Bonalive® technology from Vivoxid Ltd. Before he became Chairman and CEO, he completed a post-doc and worked in project management at Novartis Pharma in Switzerland. In addition, Dr. Ollila was also the Global Director of Sales and Marketing at Vivoxid Ltd. He holds a PhD in biochemistry and has an international background, having lived in Finland, Spain, Switzerland and the USA.
Mr. Lucchesi holds a Bachelor of Science in Engineering and joined Bonalive in 2009, after holding several positions as a Research Scientist, Business Development Manager and R&D Manager in different organizations. He has thorough knowledge of the Bonalive technologies and brings his vast experience to the company. Mr. Lucchesi coordinates Bonalive’s scientific projects and oversees their technological development.
Mrs. Rantala joined Bonalive in 2009 after having held several positions in R&D, quality control and project management. A process-oriented thinker, Rantala believes in a lean working philosophy and mentor-based leadership. She holds a degree in laboratory sciences and is a member of the Finnish Production Management Association.
Mrs. Lumiainen joined Bonalive in 2009, after having worked for Vivoxid Ltd since 2002. She has vast experience in marketing and product management, brand design and HR tasks. She holds a Master of Science in Social Sciences and Bachelor of Science in Business Administration.
Ms. Valtanen joined Bonalive in 2011 adding her significant experience in project management, corporate financing and accounting to the company. Ms. Valtanen holds a Master of Science in Economics and Business Administration.
Currently on maternity leave
Mrs Laine joined Bonalive 2020. She has a wide experience from finance, controlling and project management and has held positions for example as a Business Controller and Finance Director. She holds a Bachelor of Business and Administration.
Board of Directors
Dr. Ollila has served as Member of the Board of Directors since 2009 and assumed the role of Chairman of the Board in 2018. He founded Bonalive Biomaterials Ltd in 2009 through a management buy-out of the Bonalive® technology from Vivoxid Ltd. Before his current position as a Chairman and CEO of Bonalive, Dr. Ollila completed a post-doctoral thesis and worked at Novartis Pharma in Switzerland for several years. He was also the Global Director of Sales and Marketing at Vivoxid Ltd. Ollila holds a doctorate in biochemistry from Åbo Akademi University.
Assoc. Prof. Frantzén has been a Member of the Board of Directors since 2013. As a consultant neurosurgeon and Associate Professor at the Turku University Hospital, Frantzén has extensive experience in the clinical use of bioactive glass in spine surgery. Frantzén holds a PhD in Neurosurgery from the University of Turku.
Mr. Muñoz has been a Member of the Board of Directors since 2017. He has extensive international experience from China, India and Colombia. Currently he serves as a New Business Manager (NBO) and Business Development Director at Avalon Pharmaceuticals.
Mr. Rönnlund was appointed to the Board of Directors in 2019. As a marketing and sales executive in the US and Europe, he has extensive experience from Go-To-Market strategies and brand creation. Mr. Rönnlund holds an MSc in Engineering and an MSc in Economics from Åbo Akademi University.
Mr. Kurokallio was appointed to the Board of Directions in 2020. He has vast experience from working with strategic positions such as the Partner and CEO of Aura Capital, CEO of Stick Tech, Partner of Greenstep and CFO of BCB Medical. Currently he is the General Manager of GC Nordic Ab.
Preventing antibiotic resistance within surgeryNovember 17, 2020 10:05
Published in Mediuutiset by Ville Kainu, Pfizer and Satu Honkala, Bonalive Biomaterials: The European Antibiotic Awareness Day takes place on November 18. The campaign seeks to raise awareness on antibiotic...
Prevención de la resistencia a los antibióticos en la cirugíaNovember 17, 2020 10:01
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: La resistencia de las bacterias a los antibióticos ha aumentado a escala mundial, fenómeno que se conoce como resistencia a los...
Verhindern von Antibiotikaresistenzen in der ChirurgieNovember 17, 2020 09:57
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: Die bakterielle Resistenz gegen Antibiotika hat weltweit zugenommen. Dieses Phänomen ist als Antibiotikaresistenz bekannt. Schätzungen zeigen, dass jährlich etwa 700.000 Menschen...
Prevenzione dell’antibiotico-resistenza in ambito chirurgicoNovember 17, 2020 09:51
Mediuutiset | Ville Kainu, Pfizer, Satu Honkala, Bonalive Biomaterials: A livello globale, la resistenza batterica agli antibiotici è aumentata. Tale fenomeno è noto come resistenza agli antibiotici o antibiotico-resistenza. Si...
Prevenção da resistência aos antibióticos na cirurgiaNovember 17, 2020 09:26
Mediuutiset | Ville Kainu, Pfizer & Satu Honkala, Bonalive Biomaterials: A resistência bacteriana aos antibióticos aumentou a uma escala global. Este fenômeno é conhecido como resistência aos antibióticos. Estimativas indicam...
Highlight of the month OctoberOctober 19, 2020 10:46
By obliterating the mastoid with Bonalive® granules* after Canal Wall Down (CWD) surgery, patients have less cholesteatoma recidivism and less problems associated with their changed middle ear anatomy. Watch the...
The Smart Healing™ blogSeptember 29, 2020 09:09
The Bonalive promise of Smart Healing™ was launched in 2018 to define the core values that have contributed to the success of Bonalive Biomaterials Ltd during its 10-year company history....
How the choice of biologics might change in future surgerySeptember 28, 2020 11:18
The World Health Organization has remained concerned about the declining investments and lack of innovation in the development of new antimicrobial treatments. In orthopedics, infection-related challenges are threatening the form...
Indication of the month (September): TraumaSeptember 1, 2020 12:25
The Bonalive® granules product maintains its volume effectively, naturally stimulates bone formation and inhibits bacterial growth. The granules can be used in large defects, such as post-traumatic cases of infection,...
The Bonalive storyAugust 26, 2020 16:14
Did you know that the idea of making glass into bone was already invented in the 1960s? Read the full story behind Bonalive bioactive glass here.
Indication of the month (August)August 15, 2020 08:00
An easy-to-use, highly moldable biomaterial for bone regeneration, Bonalive® putty is ideally used as an autograft expander in spine fusion surgery. The Bonalive® putty MIS delivery system enables easy and...
Patient case: Chronic bone infectionJune 26, 2020 08:25
A 13 year old boy was diagnosed with chronic osteomyelitis in the distal tibia. He was operated 8 times and received a large amount of antibiotics and painkillers, but the...
Message from the CEO: Gearing up for a new normalJune 23, 2020 12:49
At Bonalive, we have focused our activities these last few months on targeted projects to redefine our approach to the realities brought about by COVID-19. Our most critical services in...
Video libraryMay 25, 2020 15:01
Get access to the following videos: scientific presentations surgical techniques interviews with surgeons webinars
Brochure libraryMay 15, 2020 13:31
Read our indication-specific brochures, including: – product and technology overview – clinical areas of use – patient cases
Mitteilung des GeschäftsführersMarch 27, 2020 17:11
Während ich dieses Schreiben aufsetze, sind wir weit davon entfernt, Schlussfolgerungen hinsichtlich der globalen Auswirkungen, die das Virus zeitigen wird, zu ziehen. Es wird jedoch mit aller Deutlichkeit klar, dass...
Messaggio dal CEOMarch 27, 2020 16:20
Mentre vi scrivo, è troppo presto per trarre conclusioni di ampia portata sugli effetti globali del virus. Ciò che è chiaro, tuttavia, è che, come è già successo in passato,...
Message du PDGMarch 27, 2020 16:19
En écrivant ces mots, il est bien trop tôt pour tirer des conclusions de grande portée sur les effets globaux du virus. Par contre, ce qui est sûr, c’est que...
Mensaje del CEOMarch 27, 2020 16:09
En el momento en que escribo estas líneas, aún es demasiado pronto para sacar conclusiones de mayor proyección sobre los efectos globales del virus. Sin embargo, lo que sí está...
Mensagem do CEOMarch 27, 2020 16:07
Enquanto escrevo este texto, sei que é muito cedo para tirar conclusões em longo prazo sobre os efeitos globais do vírus. O que é evidente, porém, é que, como já...
Bonalive Biomaterials Ltd
Tel. +358 401 77 44 00
Biolinja 12, 20750 Turku, Finland
ISO 13485:2016 certified
Bonalive® granules, Bonalive® putty and Bonalive® putty MIS are CE marked products.